Immune Landscape of Pancreatic Cancer Development and Drug Resistance
- 1st Edition, Volume 5 - June 7, 2024
- Imprint: Academic Press
- Editors: Batoul Farran, Ganji Purnachandra Nagaraju
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 2 3 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 2 2 - 1
Immune Landscape of Pancreatic Cancer Development and Drug Resistance explores advances in immune-based therapies aimed at harnessing the power of the immune system against p… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteImmune Landscape of Pancreatic Cancer Development and Drug Resistance explores advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters, the book discusses our current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer.
This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of advances in immunotherapy in pancreatic cancer.
- Summarizes the potential combination strategies and latest clinical trials in pancreatic cancer
- Provides an in-depth overview of our current understanding of pancreatic cancer development, including its mutational and immune features
- Explores some of the new immune-based therapies aimed at targeting PC
- Shows pancreatic cancer progression and basic elements in tumor microenvironments and their role in PC progression, also covering immunotherapy strategies
Graduate students and researchers in cancer research Oncologists, clinicians
- Cover image
- Title page
- Table of Contents
- Front Matter
- Copyright
- Dedication
- Cover Image Insert
- Aims and Scope of Series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editors
- Preface
- Contributors
- Chapter 1 Molecular profiling and mutational landscape: Possible implications in personalized medicine for treatment of pancreatic cancer
- Abstract
- Conflict of interest
- Introduction
- Molecular profiling of pancreatic cancer
- Mutational landscape of pancreatic cancer
- Therapeutic landscape of pancreatic cancer
- Role of molecular profiling in diagnosis and prognosis of pancreatic cancer
- Implications of molecular profiling and mutational landscape in personalized medicine
- Conclusion
- References
- Chapter 2 Tumor microenvironment components in pancreatic cancer
- Abstract
- Conflict of interest
- Introduction
- Tumor microenvironment in pancreatic cancer
- Conclusion
- References
- Chapter 3 Identification of immune targeted molecules in pancreatic ductal adenocarcinoma
- Abstract
- Conflict of interest
- Introduction
- PDAC: Current treatments and molecular profile
- Challenges to immunotherapy in PDAC
- PDAC tumor microenvironment (TME)
- Tumor-associated macrophages (TAMs)
- Myeloid-derived suppressor cells (MDSCs)
- Inhibition of T-cell function
- Direct inhibition via TGF-β and IL10
- Immune checkpoint receptors
- Where are we now?
- Durvalumab with or without tremelimumab for metastatic PDAC
- Napabucasin for metastatic PDAC
- Atezolizumab and cabozantinib for metastatic PDAC
- Conclusion
- References
- Chapter 4 Targeting macrophages for pancreatic cancer therapy
- Abstract
- Conflict of interest
- Introduction
- How do TAMs originate?
- Role of TAMs in PDAC inflammation
- Angiogenesis
- Metastasis
- Immunity escape
- Chemotherapy resistance
- TAMs polarization
- Conclusions and future prospects
- References
- Chapter 5 Targeting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
- Abstract
- Conflict of interest
- Introduction
- Tumor microenvironment
- Cancer-associated fibroblasts
- Quiescent cancer-associated fibroblasts
- Activated cancer-associated fibroblasts
- PDAC-associated fibroblast populations and their paracrine signaling
- Therapeutic targets of cancer-associated fibroblasts
- Targeting approaches for cancer-associated fibroblasts
- CAF causing therapeutic resistance
- Conclusion
- References
- Chapter 6 Targeting short-lived immunosuppressive myeloid cells for PDAC therapy
- Abstract
- Conflict of interest
- Introduction
- Myeloid-derived suppressor cells
- Tumor-associated macrophages
- Dendritic cells
- Importance of targeting myeloid immunosuppression
- Different examples of short-lived myeloid immunosuppression in PDAC
- Concluding remarks
- References
- Chapter 7 Regulatory T-cells in pancreatic cancer
- Abstract
- Conflict of interest
- Introduction
- Tregs in PC
- Cancer immunotherapies
- References
- Chapter 8 Targeting Tregs in pancreatic ductal adenocarcinoma
- Abstract
- Conflict of interest
- Introduction
- What are Tregs and their function
- Tregs in the tumor microenvironment
- Relationship between Tregs and outcomes
- Tregs as therapeutic targets
- Targeting immune checkpoints (IC) on Tregs
- Summary
- References
- Chapter 9 Immune modulators for pancreatic ductal adenocarcinoma therapy
- Abstract
- Conflict of interest
- Introduction
- PDAC tumor microenvironment, immunogenicity, and immune failure
- PDAC genetic markers and targetable subtypes
- Immunotherapy in PDAC
- Agonists acting at Toll-like-receptors
- Agonists of the stimulator of interferon genes
- Oncolytic viruses
- Adoptive cell therapies
- Cancer vaccines
- Wilms’ tumor-1 vaccine
- Vaccines directed against the VEGF receptor
- Kinesin family member 20A protein
- Survivin
- Mesothelin
- Other common cancer vaccines
- Local ablation along with immunotherapy
- Summary
- References
- Chapter 10 Precision medicine for PDAC immunotherapy
- Abstract
- Conflict of interest
- Introduction
- Precision medicine targets of immunotherapy
- Precision medicine combining both chemotherapy and immunotherapy
- Conclusion
- References
- Chapter 11 Application of artificial intelligence and machine learning in pancreatic cancer immunotherapy
- Abstract
- Conflict of interest
- Introduction
- Challenges in the field
- Pancreatic cancer
- Applications of AI/ML in pancreatic cancer immunotherapy
- Precision medicine and predictive modeling
- Challenges and future perspectives
- References
- Chapter 12 Enigmatic role of T cells in pancreatic ductal adenocarcinoma: An introspective study
- Abstract
- Conflict of interest
- Introduction
- Tumor microenvironment of PDAC
- Role of T-cells in the progression and pathogenesis of PDAC
- T-cell phenotypes playing a crucial role in PDAC
- Mechanisms behind T-cell exhaustion in PDAC
- Status of T-cell-based immunotherapy in PDAC
- Conclusion
- References
- Chapter 13 Delivery strategies of immunotherapies in the treatment of pancreatic cancer
- Abstract
- Conflict of interest
- Introduction
- Cancer immunotherapy
- Delivery strategies for immunotherapy
- Conclusion
- References
- Chapter 14 Current clinical trials in pancreatic ductal adenocarcinoma immunotherapy
- Abstract
- Conflict of interest
- Introduction
- PDAC current therapeutic options
- Common chemotherapy regimens
- PDAC radiation therapy
- Limitations: Limitations of current therapeutic options
- Gemcitabine resistance
- Immunotherapy in cancer
- Immune checkpoint inhibitors
- Application of immunotherapy for PDAC
- Clinical trials
- Conclusion
- References
- Chapter 15 Managing adverse effects of novel immunotherapy in pancreatic cancer
- Abstract
- Conflict of interest
- Introduction
- Immunotherapy
- Immune-checkpoint inhibitors
- Side effects and management of immunotherapy
- Conclusions and future perspectives
- References
- Chapter 16 Cathepsin B: Structure-function, metastatic role, and prognostic value in pancreatic carcinoma
- Abstract
- Conflict of interest
- Introduction
- Structure-functional properties of cathepsin B and its metastatic role in pancreatic carcinoma
- Cathepsin B as a cancer target
- Prognostic values of cathepsin B in pancreatic carcinoma
- Conclusions and future perspectives
- References
- Index
- Edition: 1
- Volume: 5
- Published: June 7, 2024
- No. of pages (Hardback): 312
- No. of pages (eBook): 330
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443235238
- eBook ISBN: 9780443235221
BF
Batoul Farran
Batoul Farran is an associate scientist in the Department of Oncology at the Albert Einstein College of Medicine, USA. She obtained her PhD in Structural and Molecular Biology from University College London, UK. She completed her postdoctoral fellowship at the Department of Hematology and Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, USA. Her work focuses on translational cancer research, specifically on targeted and immune therapies in colorectal, pancreatic and lung cancers. She has authored several publications in highly reputed international journals.
Affiliations and expertise
Associate scientist,Department of Oncology, Albert Einstein College of Medicine, Bronx, USAGN
Ganji Purnachandra Nagaraju
Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Affiliations and expertise
Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, USARead Immune Landscape of Pancreatic Cancer Development and Drug Resistance on ScienceDirect